Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by pmartino
Group name EquipePM
Item Type Journal Article
Title Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability
Creator Mbatchi et al.
Author Litaty Céphanoée Mbatchi
Author Jean-Paul Brouillet
Author Alexandre Evrard
Abstract NR1I2 (PXR) and NR1I3 (CAR) are nuclear receptors that are classified as xenoreceptors. Upon activation by various xenobiotics, including marketed drugs, they regulate the transcription level of major drug-metabolizing enzymes and transporters and facilitate the elimination of xenobiotics from the body. The modulation of the activity of these two xenoreceptors by various ligands is a major source of pharmacokinetic variability of environmental origin. NR1I2 and NR1I3 genetic polymorphisms can affect the pharmacokinetics and therapeutic response to many drugs, such as irinotecan, tacrolimus and atazanavir. This review provides an overview of NR1I2 and NR1I3 pharmacogenetic studies in various therapeutic fields (oncology, immunomodulation and infectiology) and discusses the implementation of NR1I2 and NR1I3 genetic polymorphism testing in the clinical routine.
Publication Pharmacogenomics
Volume 19
Issue 1
Pages 61-77
Date Jan 2018
Journal Abbr Pharmacogenomics
Language eng
DOI 10.2217/pgs-2017-0121
ISSN 1744-8042
Library Catalog PubMed
Call Number IMPACT: 2.302
Extra IMPACT: 2.302 PMID: 29199543
Tags clinic, Humans, pharmacogenetics, pharmacokinetics, Polymorphism, Genetic, Receptors, Cytoplasmic and Nuclear, Receptors, Steroid, review, selection, Xenobiotics, xenoreceptors
Date Added 2018/07/20 - 09:37:20
Date Modified 2021/03/05 - 10:44:17


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés